Factors affecting the association betweenoverall survival and progression-free survival in clinical trials of first-linetreatment for patients with advanced non-small cell lung cancer

摘要

PurposeNew treatment strategies, particularly the introduction of molecular-targeted agents and appropriate patient selection based on histology and/or genotyping, have progressed markedly in recent years, and the overall survival (OS) in advanced non-small cell lung cancer (NSCLC) patients has improved. The aim of the study was to identify factors affecting longer OS than that estimated from progression-free survival (PFS) in first-line treatment for advanced NSCLC.